BENZACLIN
LOE ApproachingNDATOPICALGEL
Approved
Dec 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
BENZACLIN by Bausch + Lomb is clinical pharmacology an in vitro percutaneous penetration study comparing benzaclin topical gel and topical 1% clindamycin gel alone, demonstrated there was no statistical difference in penetration between the two drugs. First approved in 2000.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BENZACLIN is a topical gel combination product containing clindamycin and benzoyl peroxide, approved in 2000 for acne vulgaris. It works through dual mechanism: clindamycin provides antibacterial activity against Propionibacterium acnes, while benzoyl peroxide concentrates in sebaceous follicles and is converted to benzoic acid. Systemic exposure is minimal (<1% for clindamycin, <2% for benzoyl peroxide).
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30% competitive intensity), indicating consolidating team focus and transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY An in vitro percutaneous penetration study comparing BenzaClin Topical Gel and topical 1% clindamycin gel alone, demonstrated there was no statistical difference in penetration between the two drugs. Mean systemic bioavailability of topical clindamycin in BenzaClin Topical Gel…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BENZACLIN offers limited active career opportunity due to zero current linked job postings and LOE-approaching lifecycle stage. Roles available are primarily in commercial maintenance and market defense rather than growth or innovation-focused functions.
Worked on BENZACLIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.